Objective To provide evidence-based recommendations regarding the diagnosis and
management of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis …

The obesity epidemic is closely associated with the rising prevalence and severity of
nonalcoholic fatty liver disease (NAFLD): obesity has been linked not only with simple …

Abbreviations: AASLD, American Association for the Study of Liver Diseases; AI, artificial
intelligence; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUROC …

OBJECTIVE Cotadutide, a dual GLP-1 and glucagon receptor agonist, is under development
for nonalcoholic steatohepatitis (NASH) and chronic kidney disease with type 2 diabetes …

Background Nonalcoholic fatty liver disease (NAFLD) comprises hepatic alterations with
increased lipid accumulation (steatosis) without or with inflammation (nonalcoholic …

To date, non-alcoholic fatty liver disease (NAFLD) is the most frequent liver disease,
affecting up to 70% of patients with diabetes. Currently, there are no specific drugs available …

The worldwide prevalence of non-alcoholic fatty liver disease (NAFLD) is estimated to have
reached 25% or more in adults. NAFLD is prevalent in obese individuals, but may also affect …

Aims/hypothesis Liraglutide, a daily injectable glucagon-like peptide-1 receptor (GLP-1r)
agonist, has been shown to reduce liver fat content (LFC) in humans. Data regarding the …

The gastrointestinal tract—the largest endocrine network in human physiology—
orchestrates signals from the external environment to maintain neural and hormonal control …

Nonalcoholic fatty liver disease (NAFLD) is a spectrum of disease, extending from simple
steatosis to inflammation and fibrosis with a significant risk for the development of cirrhosis. It …